Skip to Content
Merck
All Photos(1)

Documents

L8533

Sigma-Aldrich

Lansoprazole

≥98% (TLC), powder

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H14F3N3O2S
CAS Number:
Molecular Weight:
369.36
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (TLC)

form

powder

color

off-white

originator

Novartis

storage temp.

2-8°C

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Gastric proton pump inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T B Bödvarsdóttir et al.
Diabetologia, 53(10), 2220-2223 (2010-06-30)
Gastrin has been implicated in islet growth/neogenesis, and proton pump inhibitors (PPIs) have been shown to increase endogenous gastrin levels in animals and humans. Therefore, we investigated the effect of PPIs in a model of type 2 diabetes, Psammomys obesus.
L B Barradell et al.
Drugs, 44(2), 225-250 (1992-08-01)
Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus. Results of short term (less than 8 weeks) clinical
Lin Ye et al.
Journal of cellular and molecular medicine, 25(5), 2703-2713 (2021-02-20)
Acute kidney injury (AKI) is the main obstacle that limits the use of cisplatin in cancer treatment. Proton pump inhibitors (PPIs), the most commonly used class of medications for gastrointestinal complications in cancer patients, have been reported to cause adverse
Grace Chai et al.
Pediatrics, 130(1), 23-31 (2012-06-20)
To describe trends in outpatient prescription drug utilization in US children and the changes in major areas of pediatric therapeutic use for the years 2002 through 2010. Large prescription databases (the IMS Vector One: National and Total Patient Tracker) were
Hala H Mosli et al.
The Journal of clinical endocrinology and metabolism, 97(9), E1731-E1735 (2012-06-23)
Chromogranin A (CgA) is used as a generic tumor marker for neuroendocrine tumors. Proton pump inhibitors (PPI) are known to increase CgA, but it is not clear to what extent, and there is little information on how long PPI need

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service